You’re exploring CGON as your free preview. Sign up free for 3 full 5D deep-dives a month, or start a 14-day Pro trial for unlimited access to more than 3,000 US-listed stocks - no credit card.

CG Oncology Inc.· CGON

🇺🇸 US · MidBroad USNASDAQ

Healthcare Biotechnology Website

Price: $64.06
Day: +3.39%
Mkt Cap: $5.68B
52W Range: $35.80 – $80.97
Volume: 724.7K
Beta: 0.24

D35D Framework

Valuation Analysis

Intrinsic-value engines paired with peer-anchored multiples.

Valuation: 2.0 / 5 (Above estimate); at $64.06 the price is 109% above the estimate of $31, which rests on market evidence only (no valuation model)
Estimates: sector peers $31 (130 companies), own 10-year history $133 (not used without a model)

Blog

Valuation Assessment

CGON Valuation Summary

How sector peers value it. With no valuation model behind it, the estimate rests on market evidence only

Overall valuation

2.0/5

Above estimate

Market only · blended estimate

$31-52.0%

With no valuation model behind it, the estimate rests on market evidence only: the value implied by sector peers. The price is 109% above that estimate. Without a model to check it against, the score is held between 2 and 4 and the stock's own history is shown but not used.Last updated November 4, 2026.

Valuation Multiples

Per-metric breakdown of how CGON is priced relative to its sector peers, its own 10-year history, and analyst forward estimates.

Valuation context: This company is currently unprofitable with negative EBITDA. P/E and EV/EBITDA aren't meaningful; focus on EV/FCF and FCF Yield in the primary grid, plus revenue multiples (P/S, EV/Sales) in the expanded section.

What sector peers imply

Value if it traded at the sector-median multiple

What its own history implies

Value if it traded at its own 10-year median multiple

How the Multiples lens works

Five primary multiples surface the headline call; five additional multiples sit one click deeper for context.

Valuation multiples compare a company's market price to its financial fundamentals. The primary grid covers both the equity perspective (P/E, PEG, FCF Yield) and the enterprise value perspective (EV/EBITDA, EV/FCF) so you see how the market prices the company two ways simultaneously.

Price-based multiples use market cap and reflect what equity investors pay. EV-based multiples include debt and are better for comparing companies with different capital structures. The expanded section below adds P/B, P/S, P/FCF, EV/EBIT, and EV/Sales for additional perspective.

Learn more about the 5D valuation methodology

Valuation Analysis

Intrinsic-value engines paired with peer-anchored multiples.

Valuation: 2.0 / 5 (Above estimate); at $64.06 the price is 109% above the estimate of $31, which rests on market evidence only (no valuation model)

Estimates: sector peers $31 (130 companies), own 10-year history $133 (not used without a model)

CG Oncology Inc.· CGON

Valuation Analysis

Valuation Multiples

Additional valuation multiples5 more metrics: P/B Ratio, P/S Ratio, P/FCF, EV/EBIT, EV/Sales

How implied prices are calculated

Primary multiples primer

Search stocks

Valuation Analysis

Valuation Multiples

Additional valuation multiples5 more metrics: P/B Ratio, P/S Ratio, P/FCF, EV/EBIT, EV/Sales

How implied prices are calculated

Primary multiples primer